Merrill keeps Onyx at neutral

Onyx Pharmaceuticals, Inc. was maintained by Merrill Lynch analyst Eric Ende at neutral after the company reported second-quarter Nexavar sales of $32.2 million, in line with the analyst's estimate of $32.0 million and ahead of consensus of $28 million. Nexavar sales grew 36% over the first quarter. Onyx expects stable Nexavar sales through the fourth quarter of 2006, a sign growth may have peaked, according to the analyst. Shares of the Emeryville, Calif.-based biopharmaceutical company were down $1.84, or 11.84%, at $13.70, on volume of 3,390,188 shares versus the three-month running average of 1,171,580 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.